The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
about
The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholdersThe application of biomarkers in clinical trials for motor neuron diseaseLack of therapeutic interchangeability of HMG-CoA reductase inhibitors.Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpointsTranslational research in central nervous system drug discovery.C-reactive protein levels in the perioperative period as a predictive marker of endoscopic recurrence after ileo-colonic resection for Crohn's disease.Alzheimer's disease drug development: old problems require new priorities.Causal structures for evaluating statin class effects.
P2860
Q28543430-4EEC1D01-AEFF-4130-B7A1-7D047B736C9DQ33961751-393F71B9-82D5-4F2B-9722-2E388AA80426Q35009456-B4669E87-B853-4DDB-80A0-54122AC26B90Q35124348-D9748A01-F03B-4E8E-83FF-6F9BE2C34231Q36401418-4A23B891-CDCF-4B85-832C-1D395A2AC8F8Q37164209-AE4C64EE-A496-4D2A-9F70-A4960640A7EDQ37363992-085E8B9A-155B-4FCC-940A-9B871913397FQ44258134-367D6B09-A70F-49E7-A7DA-BF41BC3875EE
P2860
The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
The use of surrogate endpoints ...... ls in cardiovascular diseases.
@ast
The use of surrogate endpoints ...... ls in cardiovascular diseases.
@en
The use of surrogate endpoints ...... ls in cardiovascular diseases.
@nl
type
label
The use of surrogate endpoints ...... ls in cardiovascular diseases.
@ast
The use of surrogate endpoints ...... ls in cardiovascular diseases.
@en
The use of surrogate endpoints ...... ls in cardiovascular diseases.
@nl
prefLabel
The use of surrogate endpoints ...... ls in cardiovascular diseases.
@ast
The use of surrogate endpoints ...... ls in cardiovascular diseases.
@en
The use of surrogate endpoints ...... ls in cardiovascular diseases.
@nl
P2860
P356
P1476
The use of surrogate endpoints ...... ls in cardiovascular diseases.
@en
P2093
P2860
P304
P356
10.1002/PDS.654
P577
2001-10-01T00:00:00Z